Genetic Testing Opens the Door to Gene Therapy for Two Children With Rare Vision Loss

par Good-Lite Co 24 août 2026

par Good-Lite Co Publié le 24 août 2026Mis à jour le 24 août 2026

Mia Spicer was almost two when a Halloween evening gave her mother the first clear sign that something was wrong with her vision.

It was still early, but as Mia went trick-or-treating through the neighborhood, she stumbled and struggled to make her way in the fading light. During the day, she appeared to see well. That contrast made the problem difficult to explain and, at first, difficult to diagnose.

Her mother, Sabrena Gates, brought Mia to a pediatric ophthalmologist in Atlanta. Because Mia was very young and her daytime vision appeared normal, the family was advised to return when she had more language to describe what she was experiencing. A second evaluation months later led to similar advice. When Mia returned again in 2023, now better able to describe what she was seeing, her eyesight still appeared normal during examination.

Gates remained convinced that something was being missed and pushed for genetic testing. That decision finally provided an answer. Mia was diagnosed with Leber congenital amaurosis type 2 associated with two abnormal copies of the RPE65 gene, an inherited retinal condition that can cause severe low vision, particularly in dim light, and can worsen over time.

The diagnosis did more than explain Mia’s symptoms. It identified a specific genetic cause of her vision loss and showed that she might qualify for an FDA-approved gene therapy developed for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

For a family that had spent years searching for an explanation, the genetic result did more than provide a name. It opened a path to treatment.

Vision Loss Can Be Difficult to Recognize in Very Young Children

Mia’s experience illustrates one of the challenges of identifying inherited retinal disease in early childhood. A young child may know that the world looks a certain way, but may not have the language or experience to explain that something is different. Children also adapt to the vision they have. They do not have another person’s visual experience for comparison.

That can make some vision problems easy to overlook, especially when they are most noticeable under specific conditions. In Mia’s case, daytime vision was not the clearest clue. Her difficulties emerged when light levels dropped, as they had on Halloween night.

Her experience also shows why a normal-looking eye examination does not always resolve every concern about visual function. Some inherited retinal diseases affect how retinal cells function before changes become obvious in a way that is easily recognized during a routine visit. When a child cannot yet give a detailed history, a parent’s observations about when and where vision problems appear can become especially important.

For Mia, the repeated mismatch between what her family observed and what routine evaluation seemed to show prolonged the search for an answer. Genetic testing eventually connected those observations to a specific inherited condition.

Sabrena Gates and her children Mia and Niko Spicer. Photo courtesy of Gates

Genetic Testing Provided the Missing Piece

Leber congenital amaurosis describes a group of rare inherited retinal disorders that can cause visual impairment beginning in infancy or early childhood. It is not a single genetic disease. Multiple gene variants can produce similar patterns of early vision loss, and identifying the underlying genetic cause can help clarify diagnosis, inheritance, prognosis, and whether a targeted treatment or clinical trial may be relevant.

Mia was found to have two abnormal copies of RPE65. University of Michigan Health reports that the RPE65-related condition described in her case affects roughly 1 in 50,000 to 100,000 people in the United States.

RPE65 plays an important role in the visual cycle, the biochemical process that allows the retina to respond to light. When both copies of the gene do not function properly, retinal cells cannot perform that process normally. Children with RPE65-related disease can have low vision, particularly at night, and vision may progressively worsen.

The importance of Mia’s genetic diagnosis extended beyond finally explaining why she struggled in low-light environments. Unlike most genetic causes of inherited retinal disease, confirmed biallelic RPE65 mutation-associated retinal dystrophy has an FDA-approved gene therapy available for eligible patients who have viable retinal cells.

That distinction matters because genetic testing does not automatically lead to treatment. Panels used to investigate inherited retinal disease can evaluate hundreds of genes, while only a small number of genetic causes currently have approved therapies. A molecular diagnosis may still be valuable even when there is no treatment because it can guide counseling, follow-up, family testing, and possible clinical trial eligibility. In Mia’s case, however, the result also created an immediate treatment pathway.

Mia’s Diagnosis Changed the Path for Her Brother

The diagnosis also changed what happened next for Mia’s younger brother, Niko.

Niko had the same inherited disorder, but his family did not have to repeat the same years of uncertainty. He was diagnosed before he turned two because Mia’s genetic result had already established what the family and clinicians needed to look for.

That difference between the siblings shows how one genetic diagnosis can affect an entire family. When an inherited condition is identified, siblings and other relatives may be able to receive more focused evaluation rather than waiting for symptoms to become obvious enough to describe.

For conditions that begin in infancy or early childhood, that can be especially important. A toddler who cannot explain difficulty seeing in dim light may otherwise appear cautious, hesitant, distracted, or simply unwilling to move through a dark environment. Once a family knows there is a specific inherited risk, those behaviors can be interpreted in a different context.

In the Spicer family, the long search for Mia’s diagnosis became a much shorter path to answers for Niko.

Gene Therapy Required Specialized Care Away From Home

Once Mia’s diagnosis was confirmed, her ophthalmologist connected the family with Spark Therapeutics, the company that developed Luxturna. The treatment, known generically as voretigene neparvovec-rzyl, was approved by the FDA in 2017 for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Although Luxturna represented a treatment option, receiving it was not as simple as scheduling a local procedure. University of Michigan Health reported that only 17 centers in the United States could provide the therapy and that none were located in Atlanta, where the family lived.

Gates worked in drug development for rare ophthalmic conditions, which helped her quickly identify specialists at the W.K. Kellogg Eye Center at University of Michigan Health. Members of the Michigan team had been involved in the clinical trials that supported Luxturna, and the health system was the only hospital in Michigan offering the treatment.

The family traveled from Georgia to Michigan, and Mia underwent her first surgery at C.S. Mott Children’s Hospital in May 2024. Her other eye was treated about a week later. Niko went through the same treatment process with Emily Eton, M.D., in December 2024.

The procedure involves delivering a functional copy of RPE65 to retinal cells using a modified viral vector. The goal is to give those cells the genetic instructions needed to produce functional RPE65 protein and improve the visual cycle.

Dr. Eton, a clinical assistant professor of ophthalmology and visual sciences at the University of Michigan, explained that the two eye surgeries are generally performed within a relatively short period. Once one eye has been exposed to the therapy, the immune system may respond to the viral vector, which can affect how the second eye is treated.

Luxturna is not a general treatment for Leber congenital amaurosis or inherited retinal disease as a whole. Eligibility depends on the specific genetic diagnosis and on whether enough viable retinal cells remain for treatment to be appropriate.

Everyday Moments Made the Change Visible

The most meaningful evidence of change for Mia and Niko’s family did not come from a chart or a laboratory result. It came from ordinary moments.

University of Michigan Health reports that both children showed improved vision within a day of their surgeries. While the family was staying with relatives in Jackson, Michigan, Mia was able to move around the house at night more easily. Niko, still very young, was able to pick orange slices out of a cup in the dark.

Those observations mattered because low-light vision had been one of the clearest signs of the disease. Mia’s first obvious difficulty had appeared while walking through her neighborhood on Halloween. After treatment, her family was seeing changes in the same kinds of settings that had once revealed the problem.

The children also began enjoying experiences that depend on seeing details against a dark background. They could look at fireworks and stars in the night sky. Trips to the zoo and aquarium became more visually accessible because they could better see the animals around them.

Those improvements should not be interpreted as a guarantee that gene therapy restores normal vision for every patient. Outcomes can differ, and Luxturna does not eliminate every effect of an inherited retinal disorder. What Mia and Niko’s experience does show is how meaningful improved visual function can be when the therapy matches the specific genetic cause of disease.

For their mother, the difference was visible in the children’s independence and in experiences that had previously been difficult or inaccessible.

Long-Term Follow-Up Still Matters

The surgeries were a major milestone, but they were not the end of Mia and Niko’s care.

The children return to Michigan every six months for vision testing. Their care team continues to monitor how they are seeing and hopes that long-term follow-up will add to what clinicians know about the durability of treatment.

Dr. Eton told University of Michigan Health that Luxturna has worked well for at least ten years and that clinicians are waiting for additional data to understand how long the benefit may persist beyond that period. Framing that as an ongoing question is important. Retinal gene therapy is still a relatively young field, and long-term evidence continues to develop as treated patients are followed over time.

Luxturna’s 2017 FDA approval was a landmark because it was the first directly administered gene therapy approved in the United States for a disease caused by mutations in a specific gene. Nearly a decade later, clinicians are still learning how outcomes differ according to age, remaining retinal function, disease stage, and other individual factors.

At Kellogg Eye Center, teams have treated more than 35 patients between the ages of two and 31 with Luxturna, according to University of Michigan Health. Each patient adds to the growing body of real-world experience with a treatment that was not available to families a generation ago.

One Approved Therapy Shows How Much Work Remains

Luxturna demonstrates what can become possible when researchers identify a genetic cause of vision loss and develop a therapy that targets it. It also highlights how uncommon that situation still is.

Gates noted that genetic panels for inherited vision loss may screen roughly 330 to 350 genes. Only a few of those genetic conditions currently have treatments, and many potential therapies remain in clinical trials.

For families, that means genetic testing may provide an exact diagnosis without providing an immediate treatment. The result can still be valuable because it can clarify inheritance, connect families with specialists, guide monitoring, and identify opportunities for future research. But the gap between knowing the cause of a disease and having a therapy for it remains large.

Mia and Niko happened to have one of the rare inherited retinal conditions for which an FDA-approved targeted treatment exists. Their story therefore represents both progress and the limits of current progress.

Continued research will determine how many more families eventually have the same opportunity. Developing treatments for rare inherited retinal diseases requires laboratory science, natural-history studies, genetic characterization, clinical trials, long-term follow-up, and the willingness to learn from approaches that do not succeed as well as those that do.

Gates, whose professional work also involves rare ophthalmic disease, emphasized that research depends on both success and failure. Without that work, many children with genetic forms of vision loss will continue to face conditions for which no targeted treatment exists.

Early Answers Can Change What Comes Next

Mia’s story began with a moment that could easily have been dismissed as a toddler having trouble in the dark. Her daytime vision seemed normal, early examinations did not provide an explanation, and she was too young to clearly describe what she experienced.

What ultimately changed the trajectory was a parent who continued asking questions and a genetic test that identified the precise cause of her vision loss. That result connected Mia with specialists who could determine whether she was eligible for a treatment designed for her specific mutation.

The diagnosis changed Niko’s path as well. Because the family already knew the genetic cause, he could be diagnosed before he was old enough to describe the same symptoms his sister had struggled to explain.

Not every child with unexplained vision loss will have an inherited retinal disease, and not every genetic diagnosis will lead to an approved therapy. The broader lesson is that persistent concerns about a child’s visual behavior deserve careful attention, particularly when symptoms appear under conditions that may not be reproduced during a routine examination.

When inherited retinal disease is suspected, genetic evaluation can sometimes provide information that cannot be obtained from visual acuity testing alone. It can establish a molecular diagnosis, clarify risk for other family members, guide specialty care, and identify whether a child may be eligible for an existing therapy or future research.

For Mia and Niko, finding the genetic answer led to something their family did not know was possible when the first symptoms appeared. Their experience shows how much can change when a rare diagnosis becomes a precise one, and how much more remains to be done for families still waiting for the same kind of option.